You are here

Article Text

Article menu
Download PDFPDF
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
CASE REPORT
Massive angiomyofibroblastoma of the glans penis
  1. Sherif Monib1 and
  2. Mohamed Ibrahim2
  1. 1 General Surgery Department, West Hertfordshire Hospitals NHS Trust, Watford, UK
  2. 2 General Surgery Department, Faculty of Medicine,Fayoum University, Fayoum, Egypt
  1. Correspondence to Mr Sherif Monib, sherifmonib{at}gmail.com

Abstract

Male genital tract angiomyofibroblastoma (AMF) is a rare benign tumour, with a total of 34 cases reported in literature. We are presenting a case of AMF of the glans penis in a 68-year-old man who presented with a progressively increasing in size large lesion located on the tip of his penis. Following routine investigations, the lesion was surgically excised with no adjuvant treatment, the patient was followed-up for 5 years with no evidence of local, nodal or distant recurrence. As AMF of the glans penis is extremely rare, there is not enough literature to support management guide lines, but it appears that AMF responds very well to complete surgical excision; occasional cases of recurrence have been previously reported, so a long-term follow-up is advised.

  • urology
  • sexual health
  • genital ulcers

https://doi.org/10.1136/bcr-2019-229486

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors MI was the author responsible for the surgery, ongoing care of the patient in hospital. SM conceived the case report, researched and drafted the manuscript. Both authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.